Developer docs
API playgroundTry for free, no card

Search company profiles

Celine Biotechnologies

Full company profile

uuid02m5orj

Namestring
Celine Biotechnologies
Legal namestring
Celine Biotechnologies
Websiteurl
celinebio.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Celine Biotechnologies (operating as Celine Bio) is a US-based, privately held biotechnology company founded in 2021 that develops a precision AI platform powered by human-based data to discover novel biomarkers and enable immune rejuvenation medicine. The company's stated technical focus is early detection of complex age-related diseases, specifically cancer and solid tumors, inflammation and immune dysregulation, and neurodegenerative disease. The platform architecture is described as scalable and data-driven, processing human-based biomarker data to surface novel diagnostic and therapeutic targets, with the central thesis being that restoring immune function can extend healthspan.

The underlying technology consists of three proprietary feature layers: an AI-driven biomarker discovery engine (novel method architecture), an immune rejuvenation medicine module (domain specialization), and an early detection capability positioned on accuracy and precision. A single unified product, the "Celine Bio Platform," is offered. No patents, peer-reviewed publications, named models, or disclosed dataset scale appear in the source material, so the technical maturity is verifiable only at the positioning level. The company does not expose an API, SDK, or downloadable application; all distribution is enterprise and in-person.

Commercially, the company remains pre-revenue with no publicly disclosed pricing and no named customers. Its indicated revenue mechanics are platform licensing to pharmaceutical companies for biomarker and companion-diagnostics development, and precision medicine solutions (subscription/recurring) for cancer centers and biotech firms addressing patient stratification. The go-to-market is event-driven and CEO-led, anchored on participation in pharma accelerator and validation programs (Merck Digital Sciences Studio, J&J Innovation Lab, Novo Nordisk Bio Innovation Hub, TMC Innovation Factory, Pear VC PFC, BioTools Innovator) and on visibility at industry venues such as the Galien Forum and the Memorial Sloan Kettering Life Sciences Innovation Summit. Capital support is disclosed from Pear VC, Northpond Ventures, Microsoft for Startups, Plug and Play, and NVIDIA, with no funding-round amounts or ownership terms available.

Short descriptiontext

Celine Biotechnologies is a US biotech company building a precision AI platform on human-based data to discover biomarkers and advance immune rejuvenation medicine for early detection of cancer, inflammation, and neurodegenerative disease, targeting pharmaceutical, biotech, and oncology-center customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biomarker discovery, immune rejuvenation medicine, precision medicine AI, early disease detection, companion diagnostics
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers5132
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Prepackaged Software7372
Product category
Precision Medicine AI / Biomarker Discovery
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Biomarker Discovery Platform Licensing
TypeLicensing Royalties
Description

The company develops an AI-powered platform for biomarker discovery and immune rejuvenation medicine that could be licensed to pharmaceutical and biotechnology companies for drug development and companion diagnostics

celinebio.com
2Precision Medicine Solutions
TypeSubscription Recurring
Description

Data-driven precision care solutions targeting complex age-related diseases including cancer, inflammation, and neurodegenerative conditions

celinebio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Celine Biotechnologies develops the Celine Bio Platform, a scalable precision AI platform powered by human-based biomarker data that unlocks novel biomarkers and supports immune rejuvenation medicine. The platform is used to enable early detection of complex age-related diseases — including cancer, solid tumors, inflammation, immune dysregulation, and neurodegenerative conditions — and is positioned for biomarker discovery, companion diagnostics, and data-driven precision care for pharmaceutical, biotechnology, and clinical customers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Celine Biotechnologies offers a single unified platform focused on Precision AI for early detection and immune rejuvenation. The platform is data-driven and scalable, leveraging human-based biomarker data to restore health and extend healthspan. The company addresses complex age-related diseases including cancer, solid tumors, inflammation, immune dysregulation, and neurodegenerative diseases.

Product and service1 record
1Celine Bio Platform
CategoryPrecision Medicine AI Platform
Description

A scalable precision AI platform powered by human-based biomarker data that unlocks novel biomarkers and enables immune rejuvenation medicine. Used for biomarker discovery, companion diagnostics, and early detection of cancer, solid tumors, inflammation, immune dysregulation, and neurodegenerative diseases. Targeted at pharmaceutical companies, biotechnology firms, and leading cancer centers.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CelineBio was accepted to Johnson & Johnson Innovation Lab and received Health Equity Hero recognition. CEO was invited by Johnson & Johnson to moderate Women In Bio-San Francisco Bay Area event. Company was also selected as finalist for Johnson & Johnson Innovation and CLS QuickPitch Poster session.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CelineBio was accepted to and successfully graduated from TMC Innovation Factory program for Cancer-Fighting Cohort of Innovators. TMC is the largest medical center in the world and home to the No.1 hospital for cancer care, MD Anderson Cancer Center.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Selected as inaugural member of Merck Digital Sciences Studio - only 12 companies accepted out of over 200+ applicants. This represents a significant validation of the company's technology platform.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed among supporters and innovation ecosystem partners of CelineBio.

5Harvard Innovation Lab
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed among supporters of CelineBio, indicating academic institution partnership.

celinebio.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed among supporters of CelineBio, indicating academic institution partnership.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Selected as finalist by Novo Nordisk's Bio Innovation Hub, indicating partnership interest from Novo Nordisk.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Invited to present at MSKCC Life Sciences Innovation Summit, indicating recognition and potential partnership opportunity with a leading cancer center.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Accepted to present innovation solution at BioLabs Investor Day.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Selected to showcase innovative tech-bio platform during BioTools Innovator 2024 Road Tour in San Diego.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Notable Labs
TypeEmerging player
Description

Notable Labs uses AI-driven biomarker testing to match cancer patients to therapies. Comparable to CelineBio on the AI/biomarker/cancer-therapeutic-selection thesis.

TypeDirect peer
Description

Absci is an AI-enabled biologic drug discovery platform using generative AI and wet-lab validation. Comparable to CelineBio on the AI/biologic-discovery intersection.

TypeDirect peer
Description

Lantern Pharma uses AI to identify biomarker signatures and match oncology therapies to patients. Directly comparable to CelineBio's AI/biomarker oncology focus.

4Tempus Labs
TypeBroad incumbent
Description

Tempus is a large precision-medicine AI/data company with broad oncology and biomarker offerings. Overlaps with CelineBio's data-driven precision-care approach but at much greater scale and breadth.

TypeDirect peer
Description

Freenome applies AI to multiomics blood-based data for early cancer detection. Directly comparable to CelineBio's early-detection biomarker platform focus in oncology.

TypeDirect peer
Description

Owkin uses AI on real-world patient data to discover biomarkers and develop diagnostic and therapeutic solutions for cancer and other diseases. Closely overlaps with CelineBio's biomarker and precision-medicine positioning.

TypeBroad incumbent
Description

Schrödinger is a computational drug discovery platform combining physics-based simulation with AI. Comparable to CelineBio on AI-driven molecular discovery, with broader portfolio scope.

TypeEmerging player
Description

PathAI applies AI to pathology data for biomarker and diagnostic discovery. Comparable to CelineBio on the AI/biomarker intersection, with a pathology-specific focus.

TypeDirect peer
Description

Recursion uses AI and high-throughput biology for drug discovery across multiple disease areas. Comparable to CelineBio in applying AI to biological data to accelerate therapeutic and biomarker discovery.

TypeDirect peer
Description

Insitro is a machine-learning-driven drug discovery company combining human-based data with AI to discover therapeutics. Highly comparable to CelineBio's AI/human-data biomarker platform approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celine Biotechnologies

Precision Medicine AI / Biomarker Discoverycelinebio.com

Celine Biotechnologies is a US biotech company building a precision AI platform on human-based data to discover biomarkers and advance immune rejuvenation medicine for early detection of cancer, inflammation, and neurodegenerative disease, targeting pharmaceutical, biotech, and oncology-center customers.

What Celine Biotechnologies does

Celine Biotechnologies (operating as Celine Bio) is a US-based, privately held biotechnology company founded in 2021 that develops a precision AI platform powered by human-based data to discover novel biomarkers and enable immune rejuvenation medicine. The company's stated technical focus is early detection of complex age-related diseases, specifically cancer and solid tumors, inflammation and immune dysregulation, and neurodegenerative disease. The platform architecture is described as scalable and data-driven, processing human-based biomarker data to surface novel diagnostic and therapeutic targets, with the central thesis being that restoring immune function can extend healthspan.

The underlying technology consists of three proprietary feature layers: an AI-driven biomarker discovery engine (novel method architecture), an immune rejuvenation medicine module (domain specialization), and an early detection capability positioned on accuracy and precision. A single unified product, the "Celine Bio Platform," is offered. No patents, peer-reviewed publications, named models, or disclosed dataset scale appear in the source material, so the technical maturity is verifiable only at the positioning level. The company does not expose an API, SDK, or downloadable application; all distribution is enterprise and in-person.

Commercially, the company remains pre-revenue with no publicly disclosed pricing and no named customers. Its indicated revenue mechanics are platform licensing to pharmaceutical companies for biomarker and companion-diagnostics development, and precision medicine solutions (subscription/recurring) for cancer centers and biotech firms addressing patient stratification. The go-to-market is event-driven and CEO-led, anchored on participation in pharma accelerator and validation programs (Merck Digital Sciences Studio, J&J Innovation Lab, Novo Nordisk Bio Innovation Hub, TMC Innovation Factory, Pear VC PFC, BioTools Innovator) and on visibility at industry venues such as the Galien Forum and the Memorial Sloan Kettering Life Sciences Innovation Summit. Capital support is disclosed from Pear VC, Northpond Ventures, Microsoft for Startups, Plug and Play, and NVIDIA, with no funding-round amounts or ownership terms available.

Celine Biotechnologies firmographics

Firmographics
Name
Celine Biotechnologies
Legal name
Celine Biotechnologies
Website
https://celinebio.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Celine Biotechnologies is a US biotech company building a precision AI platform on human-based data to discover biomarkers and advance immune rejuvenation medicine for early detection of cancer, inflammation, and neurodegenerative disease, targeting pharmaceutical, biotech, and oncology-center customers.
Ownership category
akta.pro rank

Celine Biotechnologies industry classification

Industry
Product category
Precision Medicine AI / Biomarker Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Biomarker discovery
  • Immune rejuvenation medicine
  • Precision medicine AI
  • Early disease detection
  • Companion diagnostics

Where Celine Biotechnologies is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Celine Biotechnologies business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Biomarker Discovery Platform Licensing: The company develops an AI-powered platform for biomarker discovery and immune rejuvenation medicine that could be licensed to pharmaceutical and biotechnology companies for drug development and companion diagnostics
  2. Precision Medicine Solutions: Data-driven precision care solutions targeting complex age-related diseases including cancer, inflammation, and neurodegenerative conditions

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Celine Biotechnologies product offering

Product offering

Core offering

Celine Biotechnologies develops the Celine Bio Platform, a scalable precision AI platform powered by human-based biomarker data that unlocks novel biomarkers and supports immune rejuvenation medicine. The platform is used to enable early detection of complex age-related diseases — including cancer, solid tumors, inflammation, immune dysregulation, and neurodegenerative conditions — and is positioned for biomarker discovery, companion diagnostics, and data-driven precision care for pharmaceutical, biotechnology, and clinical customers.

Product overview

Celine Biotechnologies offers a single unified platform focused on Precision AI for early detection and immune rejuvenation. The platform is data-driven and scalable, leveraging human-based biomarker data to restore health and extend healthspan. The company addresses complex age-related diseases including cancer, solid tumors, inflammation, immune dysregulation, and neurodegenerative diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • Celine Bio Platform A scalable precision AI platform powered by human-based biomarker data that unlocks novel biomarkers and enables immune rejuvenation medicine. Used for biomarker discovery, companion diagnostics, and early detection of cancer, solid tumors, inflammation, immune dysregulation, and neurodegenerative diseases. Targeted at pharmaceutical companies, biotechnology firms, and leading cancer centers.

Companies that use Celine Biotechnologies

Customer profile

Segments3 records

Ideal customer profiles3 records

Celine Biotechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Celine Biotechnologies partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, flagship and minor.

  • Johnson & Johnson InnovationcoreStrategic or Co-development PartnerCelineBio was accepted to Johnson & Johnson Innovation Lab and received Health Equity Hero recognition. CEO was invited by Johnson & Johnson to moderate Women In Bio-San Francisco Bay Area event. Company was also selected as finalist for Johnson & Johnson Innovation and CLS QuickPitch Poster session.
  • Texas Medical Center (TMC)coreStrategic or Co-development PartnerCelineBio was accepted to and successfully graduated from TMC Innovation Factory program for Cancer-Fighting Cohort of Innovators. TMC is the largest medical center in the world and home to the No.1 hospital for cancer care, MD Anderson Cancer Center.
  • Merck Digital Sciences StudioflagshipStrategic or Co-development PartnerSelected as inaugural member of Merck Digital Sciences Studio - only 12 companies accepted out of over 200+ applicants. This represents a significant validation of the company's technology platform.
  • Plug and PlayminorStrategic or Co-development PartnerListed among supporters and innovation ecosystem partners of CelineBio.
  • Harvard Innovation LabminorStrategic or Co-development PartnerListed among supporters of CelineBio, indicating academic institution partnership.
  • MIT Innovation CenterminorStrategic or Co-development PartnerListed among supporters of CelineBio, indicating academic institution partnership.
  • Novo Nordisk Bio Innovation HubminorStrategic or Co-development PartnerSelected as finalist by Novo Nordisk's Bio Innovation Hub, indicating partnership interest from Novo Nordisk.
  • Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerInvited to present at MSKCC Life Sciences Innovation Summit, indicating recognition and potential partnership opportunity with a leading cancer center.
  • BioLabsminorStrategic or Co-development PartnerAccepted to present innovation solution at BioLabs Investor Day.
  • BioTools InnovatorminorStrategic or Co-development PartnerSelected to showcase innovative tech-bio platform during BioTools Innovator 2024 Road Tour in San Diego.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Celine Biotechnologies competitors and assessment

Company assessment

Emerging players

  • Notable Labs: Notable Labs uses AI-driven biomarker testing to match cancer patients to therapies. Comparable to CelineBio on the AI/biomarker/cancer-therapeutic-selection thesis.
  • PathAI: PathAI applies AI to pathology data for biomarker and diagnostic discovery. Comparable to CelineBio on the AI/biomarker intersection, with a pathology-specific focus.

Direct peers

  • Absci: Absci is an AI-enabled biologic drug discovery platform using generative AI and wet-lab validation. Comparable to CelineBio on the AI/biologic-discovery intersection.
  • Lantern Pharma: Lantern Pharma uses AI to identify biomarker signatures and match oncology therapies to patients. Directly comparable to CelineBio's AI/biomarker oncology focus.
  • Freenome: Freenome applies AI to multiomics blood-based data for early cancer detection. Directly comparable to CelineBio's early-detection biomarker platform focus in oncology.
  • Owkin: Owkin uses AI on real-world patient data to discover biomarkers and develop diagnostic and therapeutic solutions for cancer and other diseases. Closely overlaps with CelineBio's biomarker and precision-medicine positioning.
  • Recursion Pharmaceuticals: Recursion uses AI and high-throughput biology for drug discovery across multiple disease areas. Comparable to CelineBio in applying AI to biological data to accelerate therapeutic and biomarker discovery.
  • Insitro: Insitro is a machine-learning-driven drug discovery company combining human-based data with AI to discover therapeutics. Highly comparable to CelineBio's AI/human-data biomarker platform approach.

Broad incumbents

  • Tempus Labs: Tempus is a large precision-medicine AI/data company with broad oncology and biomarker offerings. Overlaps with CelineBio's data-driven precision-care approach but at much greater scale and breadth.
  • Schrödinger Inc. Schrödinger is a computational drug discovery platform combining physics-based simulation with AI. Comparable to CelineBio on AI-driven molecular discovery, with broader portfolio scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Celine Biotechnologies social profiles

Digital presence

Celine Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celine Biotechnologies leadership team

Management profile

Number of profiles

Profiles1 record

Celine Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celine Biotechnologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celine Biotechnologies

What does Celine Biotechnologies do?

Celine Biotechnologies develops the Celine Bio Platform, a scalable precision AI platform powered by human-based biomarker data that unlocks novel biomarkers and supports immune rejuvenation medicine. The platform is used to enable early detection of complex age-related diseases — including cancer, solid tumors, inflammation, immune dysregulation, and neurodegenerative conditions — and is positioned for biomarker discovery, companion diagnostics, and data-driven precision care for pharmaceutical, biotechnology, and clinical customers.

Is Celine Biotechnologies a public or private company?

Celine Biotechnologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Celine Biotechnologies founded?

Celine Biotechnologies was founded in 2021. It employs 11 to 50 people.

Where is Celine Biotechnologies based?

Celine Biotechnologies is headquartered in Boston, United States, in the North America region.

How does Celine Biotechnologies make money?

Two revenue lines are on record. Biomarker Discovery Platform Licensing is the primary driver. The others are precision Medicine Solutions.

Who are Celine Biotechnologies's main competitors?

Emerging players on record are Notable Labs and PathAI. Direct peers are Absci, Lantern Pharma, Freenome, Owkin, Recursion Pharmaceuticals and Insitro. Broad incumbents are Tempus Labs and Schrödinger Inc..

Does Celine Biotechnologies have an API?

No public API is recorded for Celine Biotechnologies.

What industry is Celine Biotechnologies in?

Celine Biotechnologies's product category is Precision Medicine AI / Biomarker Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals